TM Libreria di composti

<p>The Diversity Core Library Part 1 comprises over 50,000 compounds selected from a pool of 1.6 million compounds. This collection emphasizes the diversity of compound structures obtained after filtering out PAINS, REOS and MedChem filters.</p>

The library offers a solution for establishing a foundation in the early stages of constructing a large screening library due to its large-scale supply and high cost-effectiveness. This foundation supports subsequent drug-like screening and cutting-edge research involving multiple targets and pathways.

<p>A unique collection of 2808 approved drugs for high throughput screening (HTS) and high content screening (HCS);</p>

<p>3158 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);</p>

A unique collection of xnum EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 343 protease and proteasome inhibitors for research in chemical genomics, and drug screening;

<p>A unique collection of xnum microtubule-targeted compounds can be used in HTS and HCS;</p>

<p>xnum well-chosen unique AMPK-targeted small molecules；</p>

Well-chosen 953 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new

<p>A unique collection of 420 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with</p>

<p>A unique collection of 759 cytoskeleton-related compounds, can be used for HTS and HCS；</p>

<p>Well-chosen xnum compounds with unique structures targeting transcription factor;</p>

<p>A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;</p>

<p>A unique collection of xnum GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target</p>

<p>A unique collection of 531 nuclear receptor signaling targeted compounds for high throughput and high content screening;</p>

<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>

<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>

<p>Contains xnum active small molecules for research related to post-translational modifications (PTMs);</p>

<p>A unique collection of 1040 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening;</p>